Screener
Kymera Therapeutics KYMR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (2,963) | 337 | (8,957) | 1,764 |
| Total comprehensive loss | $(64,174) | $(76,277) | $(139,402) | $(140,431) |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's net income?
- Kymera Therapeutics (KYMR) reported net income of -$61.21M in Q2 2026.
- How has Kymera Therapeutics's net income changed year-over-year?
- Kymera Therapeutics's net income increased by 20.1% year-over-year, from -$76.61M to -$61.21M.
- What is the long-term trend for Kymera Therapeutics's net income?
- Over 4 years (2021 to 2025), Kymera Therapeutics's net income has grown at a 32.8% compound annual growth rate (CAGR), from -$100.22M to -$311.35M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Kymera Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude